While the success of autologous chimeric antigen receptors (CAR) T-cell medicines cannot be denied, with the recent approvals of Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) paving the way, there are still some limitations to use autologous cells as starting materials including cost, production time as well as possible impacts of the cancer patient’s own cells on the quality and outcomes. For this reason, developing strategies to adapt allogeneic cells for CAR T therapy has several interesting advantages.

Biopharmaceutical company Celyad recently obtained FDA approval for its Investigational New Drug (IND) application for CYAD-101, the first non–gene-edited allogeneic clinical program targeting patients with unresectable colorectal cancer in combination with standard chemotherapy.

More recently, Cellectis received FDA approval for an IND to initiate a Phase 1 clinical trial for UCARTCS1 in patients with multiple myeloma (MM) further widening the possibilities and momentum behind allogeneic CAR T cells.

Subscribirse al Directorio
Escribir un Artículo

Últimas Noticias

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Destacadas

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

En nuestro post hablamos sobre este interesante tipo de célula del si...

Nueva estrategia para facilitar la regen...

by Universitat de Barcelona

Este es el primer trabajo que aporta evidencias científicas sobre la ...

Diapositiva de Fotos